Longitudinal, real-world data to support US FDA submission
A specialist pharmaceutical company commissioned Raremark to recruit a group of people living with pouchitis, a rare gastrointestinal condition, and to track how it affects their lives over a six-month period. The objective was to generate real-world data to support a future regulatory submission to the US FDA, for approval of the company’s investigational drug.
We recruited 44 participants at baseline and retained 37 over the six months. We captured data on the impact of the condition on patients’ day-to-day lives (20 self-reported measures), including: their ability to work/study; physical and emotional aspects; and their relationships with others.
We concluded that a treatment that reduces pouchitis flares could have a positive impact on the quality of life of people living with the condition.
Download the Xperiome case study Longitudinal, real-world data to support US FDA submission.
Sign up for updates
If you’d like to receive Xperiome updates directly in your inbox, just click ‘Sign up’ and fill in your details.